10511155amend

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 08:46:27 ON 27 APR 2006
FILE 'HCAPLUS' ENTERED AT 08:46:27 ON 27 APR 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	89.35	423.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.00	-12.00

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	91.88	425.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.00	-12.00

FILE 'REGISTRY' ENTERED AT 08:46:47 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS

for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend1.str



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 14 15 16 17 18 19 20 21 22
chain bonds :
10-11 11-12 12-14
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 14-15 14-19 15-16 16-17 16-20
17-18 17-22 18-19 20-21 21-22
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12 12-14 16-20 17-22 20-21 21-22
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 25:CLASS
Generic attributes :
12:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 12: Limited
C,C4
N,N2

L12 STRUCTURE UPLOADED

=> d l12
L12 HAS NO ANSWERS
L12 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l12
SAMPLE SEARCH INITIATED 08:47:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12907 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 251334 TO 264946
PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L12

=> s l12 full
FULL SEARCH INITIATED 08:47:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 255970 TO ITERATE

100.0% PROCESSED 255970 ITERATIONS 4 ANSWERS
SEARCH TIME: 00.00.04

L14 4 SEA SSS FUL L12

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	592.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.00

FILE 'HCAPLUS' ENTERED AT 08:47:25 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l14
L15 1 L14

=> d ed abs ibib hitstr

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Oct 2003
GI



I

II



III

AB Title compds. I [R1 = H, A, SO2A; A = alkyl, alkoxyalkyl; D-E = R2C=CR4, R2R3C-CR4R5; R2, R3, R4, R5 = H, A, cycloalkyl, etc.; X1 = (CHR7)g, (CHR7)h-Q-(CHR8)k; Q = O, S, NR6, etc.; R6 = H, A, cycloalkyl; R7, R8, R12 = definition as given for R2-R5; g = 1-6; h, k = 0-6; p = 0-3; E = H, A, cycloalkyl, etc.; G = (un)substituted alkylene; E and G together form (un)substituted mono or bicyclic heterocycle; X2 = definition as given for X1; Z = H, (un)substituted aromatic carbocyle] and their pharmaceutically acceptable salts and formulations were prepared For example, N-alkylation of 4-(4-fluorobenzyl)piperideine with methanesulfonic ester II, e.g., prepared from indole-4-carboxylic acid Me ester in 7-steps, afforded the hydrochloride salt of indole-3-carbonitrile III after work-up. Compds. I are claimed useful as excitatory amino acid antagonists (no data provided) and as 5-HT reuptake inhibitors.

ACCESSION NUMBER: 2003:837073 HCAPLUS
DOCUMENT NUMBER: 139:337888
TITLE: Preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases
INVENTOR(S): Schadt, Oliver; Boettcher, Henning; Leibrock, Joachim; Schiemann, Kai; Heinrich, Timo; Hoelzemann, Guenter; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087086	A2	20031023	WO 2003-EP3806	20030411
WO 2003087086	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10217006	A1	20031106	DE 2002-10217006	20020416
CA 2482655	AA	20031023	CA 2003-2482655	20030411
AU 2003224064	A1	20031027	AU 2003-224064	20030411
EP 1497279	A2	20050119	EP 2003-720455	20030411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005153980	A1	20050714	US 2003-511155	20030411
JP 2005523310	T2	20050804	JP 2003-584042	20030411

PRIORITY APPLN. INFO.: DE 2002-10217006 A 20020416
WO 2003-EP3806 W 20030411

OTHER SOURCE(S): MARPAT 139:337888

IT **615569-38-5P 615569-40-9P 615569-41-0P 615569-77-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases)

RN 615569-38-5 HCAPLUS
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-6-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-40-9 HCAPLUS
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-4-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 615569-41-0 HCAPLUS
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-77-2 HCAPLUS
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

```
=> fil reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       7.64     600.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -0.75     -12.75

FILE 'REGISTRY' ENTERED AT 08:48:12 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 APR 2006  HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES:  26 APR 2006  HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend2.str
```






```
chain nodes :
10  11  12
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
```

10-11 11-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS
Generic attributes :
12:
Saturation   : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System   : Monocyclic

Element Count :
Node 12: Limited
    C,C4
    N,N2

L16   STRUCTURE UPLOADED

=> d l16
L16 HAS NO ANSWERS
L16   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l16
SAMPLE SEARCH INITIATED 08:49:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   134667 TO ITERATE

  1.5% PROCESSED   2000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS: 2671670 TO 2715010
PROJECTED ANSWERS: 0 TO   0

L17 0 SEA SSS SAM L16

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend3.str



chain nodes :
10 11 12
ring nodes :
1 2 3 4 5 6 7 8 9 17 18 19 20 21 22
chain bonds :
10-11 11-12 12-17
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 17-18 17-22 18-19 19-20 20-21
21-22
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12 12-17
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
Generic attributes :
12:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 12: Limited
C,C4
N,N2

L18 STRUCTURE UPLOADED

=> d l18
L18 HAS NO ANSWERS
L18 STR



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend4.str



chain nodes :
10 11 12 17
ring nodes :
1 2 3 4 5 6 7 8 9 18 19 20 21 22 23
chain bonds :
10-11 11-12 12-17 17-18
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 18-19 18-23 19-20 20-21 21-22
22-23
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12 12-17 17-18
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6 18-19 18-23 19-20 20-21 21-22 22-23

G1:CH2,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom
Generic attributes :
12:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 12: Limited
C,C4
N,N2

L19 STRUCTURE UPLOADED

=> d l19
L19 HAS NO ANSWERS
L19 STR



G1 CH2,O

Structure attributes must be viewed using STN Express query preparation.

=> s l18
SAMPLE SEARCH INITIATED 08:54:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 85537 TO ITERATE

2.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1693368 TO 1728112
PROJECTED ANSWERS: 0 TO 0

L20 0 SEA SSS SAM L18

=> s l19
SAMPLE SEARCH INITIATED 08:54:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 78632 TO ITERATE

2.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 1555970 TO 1589310
PROJECTED ANSWERS: 0 TO 0

L21 0 SEA SSS SAM L19

=> fil hcaplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST	5.28	605.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.75

FILE 'HCAPLUS' ENTERED AT 08:55:26 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s us20050153980/pn
L22           1 US20050153980/PN
                (US2005153980/PN)

=> d l22
```

L22 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:837073 HCAPLUS
DN 139:337888
TI Preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases
IN Schadt, Oliver; Boettcher, Henning; Leibrock, Joachim; Schiemann, Kai; Heinrich, Timo; Hoelzemann, Guenter; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003087086	A2	20031023	WO 2003-EP3806	20030411
	WO 2003087086	A3	20040722		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10217006	A1	20031106	DE 2002-10217006	20020416
	CA 2482655	AA	20031023	CA 2003-2482655	20030411
	AU 2003224064	A1	20031027	AU 2003-224064	20030411
	EP 1497279	A2	20050119	EP 2003-720455	20030411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005153980	A1	20050714	US 2003-511155	20030411 <--
	JP 2005523310	T2	20050804	JP 2003-584042	20030411
PRAI	DE 2002-10217006	A	20020416		
	WO 2003-EP3806	W	20030411		

OS MARPAT 139:337888

```
=> select 122 1 rn
E1 THROUGH E66 ASSIGNED

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       6.28     612.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -12.75

FILE 'REGISTRY' ENTERED AT 08:56:49 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 APR 2006  HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES:  26 APR 2006  HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s e1-e66
             1 1074-85-7/BI
               (1074-85-7/RN)
             1 1074-86-8/BI
               (1074-86-8/RN)
             1 124-63-0/BI
               (124-63-0/RN)
             1 183288-46-2/BI
               (183288-46-2/RN)
             1 39830-66-5/BI
               (39830-66-5/RN)
```

1 615569-28-3/BI
(615569-28-3/RN)
1 615569-29-4/BI
(615569-29-4/RN)
1 615569-30-7/BI
(615569-30-7/RN)
1 615569-31-8/BI
(615569-31-8/RN)
1 615569-32-9/BI
(615569-32-9/RN)
1 615569-33-0/BI
(615569-33-0/RN)
1 615569-34-1/BI
(615569-34-1/RN)
1 615569-35-2/BI
(615569-35-2/RN)
1 615569-36-3/BI
(615569-36-3/RN)
1 615569-37-4/BI
(615569-37-4/RN)
1 615569-38-5/BI
(615569-38-5/RN)
1 615569-39-6/BI
(615569-39-6/RN)
1 615569-40-9/BI
(615569-40-9/RN)
1 615569-41-0/BI
(615569-41-0/RN)
1 615569-42-1/BI
(615569-42-1/RN)
1 615569-43-2/BI
(615569-43-2/RN)
1 615569-44-3/BI
(615569-44-3/RN)
1 615569-45-4/BI
(615569-45-4/RN)
1 615569-46-5/BI
(615569-46-5/RN)
1 615569-47-6/BI
(615569-47-6/RN)
1 615569-48-7/BI
(615569-48-7/RN)
1 615569-49-8/BI
(615569-49-8/RN)
1 615569-50-1/BI
(615569-50-1/RN)
1 615569-51-2/BI
(615569-51-2/RN)
1 615569-52-3/BI
(615569-52-3/RN)
1 615569-53-4/BI
(615569-53-4/RN)
1 615569-54-5/BI
(615569-54-5/RN)
1 615569-55-6/BI
(615569-55-6/RN)
1 615569-56-7/BI
(615569-56-7/RN)
1 615569-57-8/BI
(615569-57-8/RN)

1 615569-58-9/BI
(615569-58-9/RN)
1 615569-59-0/BI
(615569-59-0/RN)
1 615569-60-3/BI
(615569-60-3/RN)
1 615569-61-4/BI
(615569-61-4/RN)
1 615569-62-5/BI
(615569-62-5/RN)
1 615569-63-6/BI
(615569-63-6/RN)
1 615569-64-7/BI
(615569-64-7/RN)
1 615569-65-8/BI
(615569-65-8/RN)
1 615569-66-9/BI
(615569-66-9/RN)
1 615569-67-0/BI
(615569-67-0/RN)
1 615569-68-1/BI
(615569-68-1/RN)
1 615569-69-2/BI
(615569-69-2/RN)
1 615569-70-5/BI
(615569-70-5/RN)
1 615569-71-6/BI
(615569-71-6/RN)
1 615569-72-7/BI
(615569-72-7/RN)
1 615569-73-8/BI
(615569-73-8/RN)
1 615569-74-9/BI
(615569-74-9/RN)
1 615569-75-0/BI
(615569-75-0/RN)
1 615569-76-1/BI
(615569-76-1/RN)
1 615569-77-2/BI
(615569-77-2/RN)
1 615569-78-3/BI
(615569-78-3/RN)
1 615569-79-4/BI
(615569-79-4/RN)
1 615569-80-7/BI
(615569-80-7/RN)
1 615569-81-8/BI
(615569-81-8/RN)
1 615569-82-9/BI
(615569-82-9/RN)
1 615569-83-0/BI
(615569-83-0/RN)
1 615569-84-1/BI
(615569-84-1/RN)
1 615569-86-3/BI
(615569-86-3/RN)
1 79-20-9/BI
(79-20-9/RN)
1 88089-29-6/BI
(88089-29-6/RN)

```
              1 92822-02-1/BI
                (92822-02-1/RN)
L23          66 (1074-85-7/BI OR 1074-86-8/BI OR 124-63-0/BI OR 183288-46-2/BI
                OR 39830-66-5/BI OR 615569-28-3/BI OR 615569-29-4/BI OR 615569-3
                0-7/BI OR 615569-31-8/BI OR 615569-32-9/BI OR 615569-33-0/BI OR
                615569-34-1/BI OR 615569-35-2/BI OR 615569-36-3/BI OR 615569-37-4
                /BI OR 615569-38-5/BI OR 615569-39-6/BI OR 615569-40-9/BI OR
                615569-41-0/BI OR 615569-42-1/BI OR 615569-43-2/BI OR 615569-44-3
                /BI OR 615569-45-4/BI OR 615569-46-5/BI OR 615569-47-6/BI OR
                615569-48-7/BI OR 615569-49-8/BI OR 615569-50-1/BI OR 615569-51-2
                /BI OR 615569-52-3/BI OR 615569-53-4/BI OR 615569-54-5/BI OR
                615569-55-6/BI OR 615569-56-7/BI OR 615569-57-8/BI OR 615569-58-9
                /BI OR 615569-59-0/BI OR 615569-60-3/BI OR 615569-61-4/BI OR
                615569-62-5/BI OR 615569-63-6/BI OR 615569-64-7/BI OR 615569-65-8
                /BI OR 615569-66-9/BI OR 615569-67-0/BI OR 615569-68-1/BI OR
                615569-69-2/BI OR 615569-70-5/BI OR 615569-71-6/BI OR 615569-72-7
                /BI OR 615569-73-8/BI OR 615569-74-9/BI OR 615569-75-0/BI OR
                615569-76-1/BI OR 615569-77-2/BI OR 615569

=> d l23 1-66
```

L23 ANSWER 1 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-86-3** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[(methylsulfonyl)oxy]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 2 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-84-1** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[(methylsulfonyl)oxy]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H14 N2 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 3 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-83-0** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H12 N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 4 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-82-9** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-4-propanoic acid, 3-cyano-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H12 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 5 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-81-8** REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Propenoic acid, 3-(3-cyano-1H-indol-4-yl)-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C13 H10 N2 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 6 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-80-7** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(4-fluorophenoxy)cyclohexyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F N2 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 7 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-79-4** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-[(2,4-difluorophenyl)methyl]cyclohexyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H26 F2 N2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 8 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-78-3** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-[(4-fluorophenyl)methyl]cyclohexyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H27 F N2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 9 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-77-2** REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C25 H25 N5 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (615569-41-0)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 10 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-76-1** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C24 H26 F N3 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (615569-31-8)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 11 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-75-0** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1-Piperazinecarbothioamide, 4-[3-(3-cyano-1H-indol-5-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H21 N5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 12 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-74-9** REGISTRY
ED Entered STN: 12 Nov 2003
CN 4-Thiazolecarboxamide, 2-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H22 N6 O S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 13 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-73-8 REGISTRY
ED Entered STN: 12 Nov 2003
CN Carbamic acid, [6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H27 N5 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 14 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-72-7 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(3-amino-2-oxo-2H-1-benzopyran-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 15 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-71-6 REGISTRY
ED Entered STN: 12 Nov 2003
CN Carbamic acid, [6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C28 H29 N5 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 16 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-70-5 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H24 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 17 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-69-2** REGISTRY
ED Entered STN: 12 Nov 2003
CN 4-Thiazolecarboxylic acid, 2-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-, ethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H25 N5 O2 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 18 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-68-1** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-[4-(3-pyridinyl)-2-thiazolyl]-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H24 N6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 19 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-67-0** REGISTRY
ED Entered STN: 12 Nov 2003
CN Acetamide, N-[4-[[1-[3-(3-cyano-1H-indol-5-yl)propyl]-4-piperidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H30 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 20 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-66-9** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H25 N7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 21 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-65-8** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(3-methoxyphenyl)-3-methyl-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H28 N4 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 22 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-64-7** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H21 N3 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 23 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-63-6** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H22 N6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 24 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-62-5** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 25 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-61-4** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[(3-pyridinylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H18 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 26 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-60-3** REGISTRY
ED Entered STN: 12 Nov 2003
CN Acetamide, N-[6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C27 H27 N5 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 27 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-59-0** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-(1H-pyrazol-1-ylmethyl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H25 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 28 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-58-9** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(4-cyano-2-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 N5 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 29 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-57-8** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(4-cyano-3-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 N5 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 30 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-56-7** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(2-cyano-3-methoxyphenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 N5 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 31 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-55-6** REGISTRY
ED Entered STN: 12 Nov 2003
CN Benzamide, 4-[[1-[3-(3-cyano-1H-indol-6-yl)propyl]-4-piperidinyl]oxy]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 32 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-54-5** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 N5 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 33 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-53-4** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(4-fluoro-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 F N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 34 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-52-3** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 F N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 35 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-51-2** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(5-cyano-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H25 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 36 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-50-1** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 F N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 37 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-49-8** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1H-indol-3-yl)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H26 N4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 38 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-48-7** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 1-(methylsulfonyl)-5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H29 N5 O3 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 39 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-47-6** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 40 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-46-5** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(8-quinolinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 41 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-45-4** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-5-carboxamide, 3-[1-[3-(3-cyano-1H-indol-5-yl)propyl]-4-piperidinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C26 H27 N5 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 42 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-44-3** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,1,3-benzothiadiazol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C22 H22 N6 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 43 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-43-2** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H27 N5 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 44 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-42-1** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1H-indol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 45 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-41-0 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 46 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-40-9 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-4-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 47 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-39-6 REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2-oxo-2H-1-benzopyran-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H24 N4 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 48 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 615569-38-5 REGISTRY
ED Entered STN: 12 Nov 2003
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-6-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C25 H25 N5 O2
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 49 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-37-4** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(4-cyanophenyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H23 N5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 50 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-36-3** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(4-fluorophenoxy)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H24 F N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 51 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-35-2** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 F N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 52 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-34-1** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 5-[3-[4-[(2,4-difluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F2 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 53 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-33-0** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-(4-fluorophenoxy)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H24 F N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 54 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-32-9** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-[(2,4-difluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F2 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 55 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-31-8** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 4-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 F N3
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 56 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-30-7** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-(4-fluorophenoxy)-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C23 H24 F N3 O
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 57 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-29-4** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-[(2,4-difluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H25 F2 N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 58 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **615569-28-3** REGISTRY
ED Entered STN: 12 Nov 2003
CN 1H-Indole-3-carbonitrile, 6-[3-[4-[(4-fluorophenyl)methyl]-1-piperidinyl]propyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H26 F N3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 59 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **183288-46-2** REGISTRY
ED Entered STN: 22 Nov 1996
CN 2-Benzofurancarboxamide, 5-(1-piperazinyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5-(1-Piperazinyl)benzofuran-2-carboxamide
CN 5-(piperazin-1-yl)benzofuran-2-carboxamide
FS 3D CONCORD
MF C13 H15 N3 O2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 60 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **92822-02-1** REGISTRY
ED Entered STN: 17 Dec 1984
CN Piperidine, 4-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 4-(4-Fluorobenzyl)piperidine
CN 4-(p-Fluorobenzyl)piperidine
CN 4-[(4-Fluorophenyl)methyl]piperidine
FS 3D CONCORD
MF C12 H16 F N
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
61 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 61 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 88089-29-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN 2-Propenoic acid, 3-(1H-indol-4-yl)-, methyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C12 H11 N O2
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L23 ANSWER 62 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 39830-66-5 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole-4-carboxylic acid, methyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole-4-carboxylic acid, methyl ester (6CI)
OTHER NAMES:
CN 4-Methoxycarbonylindole
CN Methyl 1H-indole-4-carboxylate
CN Methyl 4-indolecarboxylate
FS 3D CONCORD
MF C10 H9 N O2
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM, IFICDB, IFIPAT, IFIUDB, MSDS-OHS, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

91 REFERENCES IN FILE CA (1907 TO DATE)
91 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L23 ANSWER 63 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 1074-86-8 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole-4-carboxaldehyde (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole-4-carboxaldehyde (7CI, 8CI)
OTHER NAMES:
CN 4-Formylindole
CN 4-Indolecarbaldehyde
CN NSC 337264
FS 3D CONCORD
MF C9 H7 N O
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, IFICDB, IFIPAT, IFIUDB, NAPRALERT, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

80 REFERENCES IN FILE CA (1907 TO DATE)
80 REFERENCES IN FILE CAPLUS (1907 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L23 ANSWER 64 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN 1074-85-7 REGISTRY
ED Entered STN: 16 Nov 1984
CN 1H-Indole-4-methanol (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Indole-4-methanol (7CI, 8CI)
FS 3D CONCORD
MF C9 H9 N O
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L23 ANSWER 65 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **124-63-0** REGISTRY
ED Entered STN: 16 Nov 1984
CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Chloro methyl sulfone
CN Mesyl chloride
CN Methanesulfonic acid chloride
CN Methanesulphonyl chloride
CN Methyl sulfochloride
CN Methylsulfonyl chloride
CN NSC 15039
FS 3D CONCORD
MF C H3 Cl O2 S
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, DIPPR*, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5201 REFERENCES IN FILE CA (1907 TO DATE)
47 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5225 REFERENCES IN FILE CAPLUS (1907 TO DATE)
39 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L23 ANSWER 66 OF 66 REGISTRY COPYRIGHT 2006 ACS on STN
RN **79-20-9** REGISTRY
ED Entered STN: 16 Nov 1984
CN Acetic acid, methyl ester (6CI, 8CI, 9CI) (CA INDEX NAME)
OTHER NAMES:
CN Devoton
CN Methyl acetate
CN Methyl ethanoate
CN NSC 405071
CN Tereton
FS 3D CONCORD
MF C3 H6 O2
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CHEMSAFE, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DIPPR*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM*, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL, VTB
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8622 REFERENCES IN FILE CA (1907 TO DATE)
32 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8640 REFERENCES IN FILE CAPLUS (1907 TO DATE)
200 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.28	738.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-12.75

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:58:04 ON 27 APR 2006

10511155amend

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

10511155amend

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:03:28 ON 27 APR 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:03:33 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend5.str



chain nodes :

10 11 12 18
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
10-11 11-12 12-18
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12 12-18
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6

G1:CH2,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 18:Atom
Generic attributes :
12:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
18:
Saturation : Unsaturated

Element Count :
Node 12: Limited
C,C4
N,N2

Node 18: Limited
C,C4-9

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 CH2,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:03:51 FILE 'REGISTRY'

10511155amend

SAMPLE SCREEN SEARCH COMPLETED - 134667 TO ITERATE

1.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2671670 TO 2715010
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend7.str



chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9 12 18 19 20 21 22
chain bonds :
10-11 11-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 12-18 12-22 18-19 19-20 20-21
21-22
exact/norm bonds :
2-3 2-7 3-9 7-8 8-9 11-12 12-18 12-22 18-19 19-20 20-21 21-22
exact bonds :
10-11
normalized bonds :
1-2 1-6 3-4 4-5 5-6

G1:CH2,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 16:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
Element Count :
Node 12: Limited
C,C4
N,N2

Node 18: Limited
C,C4
N,N2

Node 19: Limited
C,C4
N,N2

Node 20: Limited
C,C4

10511155amend

N,N2

Node 21: Limited
C,C4
N,N2

Node 22: Limited
C,C4
N,N2

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 CH2,O

Structure attributes must be viewed using STN Express query preparation.

=> s l3
SAMPLE SEARCH INITIATED 12:06:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12901 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS 3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 251216 TO 264824
PROJECTED ANSWERS: 124 TO 650

L4 3 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 12:06:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 257553 TO ITERATE

100.0% PROCESSED 257553 ITERATIONS 504 ANSWERS
SEARCH TIME: 00.00.03

L5 504 SEA SSS FUL L3

=> fil hcaplus

10511155amend

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.70	168.91

FILE 'HCAPLUS' ENTERED AT 12:06:43 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L6 553 L5

=> d ed abs ibib hitstr 550-553

L6 ANSWER 550 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Six oxindoles I (RR1N = Me2CHNH, morpholino, piperidino, 4-methylpiperazino, etc.; R2 = H, Me, Et, CHMe2, Bu; R3 = H, Me, PhCH2, cyclohexyl, etc.; R4, R5 = H, Me), having β-adrenergic, antiallergic, and other activities (no data), were prepared by reducing their 4-alkynoyl analogs, e.g. II. Thus, 7.6 g 3,3-dimethyl-7-methoxyoxindole and 16 g AlCl3 in dichloroethane heated with 23 g BrCHEtCOBr at 50-60° 1.5 h gave 6.2 g 4-(2-bromobutyryl)-3,3-dimethyl-7-methoxyoxindole, which (5 g) was refluxed with Me2CHNH2 to give 6 g II.HBr (R3 = Me). Similarly prepared was II.HBr (R3 = H), which (1.1 g) was reduced with NaBH4 in aqueous MeOH at pH 7.5-8.0 to give 430 mg I.HCl.

ACCESSION NUMBER: 1978:424145 HCAPLUS
DOCUMENT NUMBER: 89:24145
TITLE: 4-(1-Hydroxy-2-aminoalkyl)oxindoles
INVENTOR(S): Yoshizaki, Shiro; Sato, Tadao; Nakagawa, Kazuyuki
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53018562	A2	19780220	JP 1976-92150	19760802
JP 59019537	B4	19840507		

PRIORITY APPLN. INFO.: JP 1976-92150 A 19760802
IT **66931-26-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 66931-26-8 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-[1-hydroxy-2-(4-methyl-1-piperazinyl)propyl]-3,3-dimethyl-7-(phenylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 550 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●2 HCl

L6 ANSWER 551 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Twenty title derivs. I (R, R1, R2, R3, R4 = H, alkyl; R5, R6 = H, alkyl, aralkyl, phenoxyalkyl; R5NR6 may form a heterocyclic ring) and their acid salts were prepared by reaction of II (X = halo) with R5R6NH. I had vasodilating and platelet aggregation inhibitory activities (no data). Thus, a mixture of 5 g PhOCH2CHMeNH2 and 5 g II (R = R1 = R3 = H, R2 = R4 = Me, X = Br) in MeCN was refluxed 5 h to give 2.73 g I.HCl (R = R1 = R3 = R5 = H, R2 = R4 = Me, R6 = PhOCH2CHMe).

ACCESSION NUMBER: 1978:62293 HCAPLUS
DOCUMENT NUMBER: 88:62293
TITLE: α-Substituted aminoalkanoyloxindole derivatives
INVENTOR(S): Nishi, Takao; Oshiro, Yasuo; Nakagawa, Kazuyuki
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52118464	A2	19771004	JP 1976-36280	19760331
JP 58040539	B4	19830906		

PRIORITY APPLN. INFO.: JP 1976-36280 A 19760331
IT **65435-49-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65435-49-6 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-methyl-5-[1-oxo-2-(1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 552 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 May 1984
GI



AB Fifteen vasodilators I, (R, R1, R2, R3, R4 = H, alkyl; R5, R6 = H, alkyl, aralkyl, phenoxyalkyl; R5NR6 may form a heterocyclic ring; Z = H,OH) and their acid salts were prepared by reduction of I (Z = O). Thus, a mixture of 2.5 g II.HCl (R = R1 = R3 = R5 = H, R2 = R4 = Me, R6 = PhOCH2CHMe) was hydrogenated at 1 kg/cm2 over 0.2 g PtO2 in EtOH 8 h at room temperature to give 24.6% I.HCl (R = R1 = R3 = R5 = H, R2 = R4 = Me, R6 = PhOCH2CHMe; Z = H,OH).

ACCESSION NUMBER: 1978:62292 HCAPLUS
DOCUMENT NUMBER: 88:62292
TITLE: Oxindole derivatives
INVENTOR(S): Nishi, Takao; Oshiro, Yasuo; Nakagawa, Kazuyuki
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 52118465	A2	19771004	JP 1976-36281	19760331
JP 58025673	B4	19830528		

PRIORITY APPLN. INFO.: JP 1976-36281 A 19760331
IT **65434-99-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 65434-99-3 HCAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-[1-hydroxy-2-(1-piperazinyl)propyl]-3-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L6 ANSWER 553 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 12 May 1984

GI For diagram(s), see printed CA Issue.

AB 4-, 5-, 6-, and 7-Cyanoindoles are converted in excellent yields into the corresponding formylindoles by sodium hypophosphite/nickel according to the method of Backeberg and Staskum (1961). Condensation of these formylindoles with nitromethane or nitroethane affords the related nitrovinylindoles, which are reduced to the title aminoalkylindoles by LiAlH4. On the other hand, 5-chloroacetylindole is aminated by reaction with various secondary amines, and the amino ketones formed are reduced to the corresponding 5-(2-amino-1-hydroxyalkyl)indoles. Friedel-Crafts condensation of 1-acetyl-7-hydroxyindoline with ClCH2COCl yields 1-acetyl-4-chloroacetyl-7-hydroxyindoline (I), which is transformed into indoline derivs. carrying a 2-amino-1-hydroxyethyl side-chain in position 4.

ACCESSION NUMBER: 1969:28749 HCAPLUS

DOCUMENT NUMBER: 70:28749

TITLE: Synthetic indole compounds. V. Syntheses of indoles with (2-aminoethyl)-, (2-aminopropyl)-, or alkanolamine side chains on the six-membered ring

AUTHOR(S): Troxler, Franz; Harnisch, A.; Bormann, G.; Seemann, F.; Szabo, L.

CORPORATE SOURCE: Pharm. Chem. Forschungslab., Sandoz. A.-G., Basel, Switz.

SOURCE: Helvetica Chimica Acta (1968), 51(7), 1616-28
CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Journal

LANGUAGE: German

IT **20996-72-9P 20996-80-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20996-72-9 HCAPLUS

CN Ketone, indol-5-yl (4-phenyl-1-piperazinyl)methyl (8CI) (CA INDEX NAME)



RN 20996-80-9 HCAPLUS

CN Indole-5-methanol, α-[(4-phenyl-1-piperazinyl)methyl]- (8CI) (CA INDEX NAME)



L6 ANSWER 553 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

10511155amend

=> d ed abs ibib hitstr 500-510

L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Jan 1998
GI



I

AB Title compds. I [R1,R2 = H, Me, OH, HOCH2, N3, NO2, (un)substituted NH2, (un)substituted alkoxy, Cl, Br, (un)substituted alkylthio, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted aryl, (un)substituted heteroaryl; R3 = H, COMe; Y = OH, OAc; X = CO2Me, CH2OH] are prepared I are useful for enhancing the function and/or survival of a trophic factor responsive cell. I inhibit interleukin-2 production and have immunosuppressive activity. Thus, I [R1, R2 = (CH2)2SMe, Y = OH, X = CO2Me, R3 = H] (II) was prepared by reduction of the corresponding COCH2SMe substituted derivative II showed 294% activity when tested at 300nM for spinal cord ChAT activity and 260% activity when tested at 250nM for basal forebrain ChAT activity as compared to the control.

ACCESSION NUMBER: 1998:1484 HCAPLUS
DOCUMENT NUMBER: 128:75237
TITLE: synthesis and neurotropic activity of selected derivatives of K-252a
INVENTOR(S): Hudkins, Robert L.; Mallamo, John P.; Hamano, Masami; Tanaka, Reiko; Murakata, Chikara
PATENT ASSIGNEE(S): Cephalon, Inc., USA; Kyowa Hakko Kogyo Co., Ltd.
SOURCE: PCT Int. Appl., 150 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9746565	A1	19971211	WO 1997-US9448	19970602
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 200632-75-3 HCAPLUS
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-5,16-bis[(4-methyl-1-piperazinyl)acetyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 200632-95-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and neurotropic activity of selected derivs. of K-252a)
RN 200632-95-7 HCAPLUS
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-

L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2256633	AA	19971211	CA 1997-2256633		19970602
AU 9732253	A1	19980105	AU 1997-32253		19970602
AU 716656	B2	20000302			
EP 918777	A1	19990602	EP 1997-927906		19970602
EP 918777	B1	20020828			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI					
BR 9711093	A	19990817	BR 1997-11093		19970602
CN 1226893	A	19990825	CN 1997-196985		19970602
NZ 333018	A	20000526	NZ 1997-333018		19970602
JP 2000511902	T2	20000912	JP 1998-500751		19970602
AT 222912	E	20020915	AT 1997-927906		19970602
PT 918777	T	20030131	PT 1997-927906		19970602
ES 2183184	T3	20030316	ES 1997-927906		19970602
RU 2205184	C2	20030527	RU 1999-100050		19970602
NO 9805622	A	19990202	NO 1998-5622		19981202
NO 312464	B1	20020513			
KR 2000016289	A	20000325	KR 1998-709862		19981203
MX 9810199	A	20000531	MX 1998-10199		19981203
HK 1018703	A1	20030411	HK 1999-103763		19990831
NZ 504097	A	20050624	NZ 2000-504097		20000419

PRIORITY APPLN. INFO.: US 1996-657366 A 19960603
WO 1997-US9448 W 19970602

OTHER SOURCE(S): MARPAT 128:75237

IT 200632-74-2P 200632-75-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and neurotropic activity of selected derivs. of K-252a)
RN 200632-74-2 HCAPLUS
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2-acetyl-10-(acetyloxy)-2,3,9,10,11,12-hexahydro-9-methyl-5,16-bis[(4-methyl-1-piperazinyl)acetyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 500 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
i][1,6]benzodiazocine-10-carboxylic acid, 2-acetyl-10-(acetyloxy)-2,3,9,10,11,12-hexahydro-5,16-bis[1-hydroxy-3-(4-methyl-1-piperazinyl)propyl]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Dec 1997
AB Claimed are a method of locating one or more salts of a compound, the salts having a solubility in a cyclodextrin equal to or greater than a desired target solubility, comprising obtaining a series of salts of the compound, measuring the equilibrium solubility of each salt in the series in the cyclodextrin, and comparing each measured solubility with the target solubility Ziprasidone mesylate was dissolved in a 300 mg/mL β-cyclodextrin sulfobutyl ether solution to make a concentration of 27.3 mg/mL. The solution was sterile filtered and filled into vials to give a product to be administered orally or by injections.
ACCESSION NUMBER: 1997:801873 HCAPLUS
DOCUMENT NUMBER: 128:66485
TITLE: Method of selecting a salt for making an inclusion complex
INVENTOR(S): Kim, Yesook
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 811386	A2	19971210	EP 1997-302821	19970424
EP 811386	A3	19990210		
EP 811386	B1	20040929		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 277641	E	20041015	AT 1997-302821	19970424
PT 811386	T	20041231	PT 1997-302821	19970424
ES 2224205	T3	20050301	ES 1997-302821	19970424
US 2001007862	A1	20010712	US 1997-850353	19970502
CA 2204451	AA	19971107	CA 1997-2204451	19970505
CA 2204451	C	20040629		

PRIORITY APPLN. INFO.: US 1996-16866P P 19960507
IT **122883-93-6DP**, Ziprasidone hydrochloride, complexes with cyclodextrin ethers **185021-64-1DP**, complexes with cyclodextrin ethers **199522-95-7DP**, complexes with cyclodextrin ethers **199522-96-8DP**, complexes with cyclodextrin ethers **199522-97-9DP**, complexes with cyclodextrin ethers **199522-98-0DP**, complexes with cyclodextrin ethers **199522-99-1DP**, complexes with cyclodextrin ethers **199523-00-7DP**, complexes with cyclodextrin ethers
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclodextrin inclusion complexes with drug salts)
RN 122883-93-6 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 199522-95-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 199522-96-8 HCAPLUS
CN 2-Naphthalenesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 185021-64-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C21 H21 Cl N4 O S



CM 2

CRN 120-18-3
CMF C10 H8 O3 S



RN 199522-97-9 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 199522-98-0 HCAPLUS
CN L-Aspartic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 56-84-8
CMF C4 H7 N O4

Absolute stereochemistry. Rotation (+).



RN 199522-99-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 199523-00-7 HCAPLUS
CN Ethanesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



IT **146939-27-7**, Ziprasidone
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of cyclodextrin inclusion complexes with drug salts)
RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **185021-64-1P 199522-99-1P 199523-00-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclodextrin inclusion complexes with drug salts)

RN 185021-64-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 199523-00-7 HCAPLUS
CN Ethanesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



L6 ANSWER 501 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 199522-99-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 27 Nov 1997
AB The compds. (I) are prepared by treatment of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one with MeSO3H. I are useful for the treatment of psychotic disorders (no data). Crystal datas of I are also presented.

ACCESSION NUMBER: 1997:746048 HCAPLUS
DOCUMENT NUMBER: 128:22903
TITLE: Preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders
INVENTOR(S): Busch, Frank Robert; Rose, Carol Anne; Shine, Russell James
PATENT ASSIGNEE(S): Pfizer Inc., USA; Busch, Frank Robert; Rose, Carol Anne; Shine, Russell James
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742191	A1	19971113	WO 1997-IB393	19970410
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 491847	B	20020621	TW 1997-86104173	19970401
AU 9721747	A1	19971126	AU 1997-21747	19970410
AU 731267	B2	20010329		
CN 1216991	A	19990519	CN 1997-194244	19970410
CN 1091769	B	20021002		
EP 918772	A1	19990602	EP 1997-914520	19970410
EP 918772	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9709889	A	19990810	BR 1997-9889	19970410
JP 11509867	T2	19990831	JP 1997-539672	19970410
JP 3494659	B2	20040209		
NZ 508304	A	20010525	NZ 1997-508304	19970410
IL 126591	A1	20011125	IL 1997-126591	19970410
CZ 289215	B6	20011212	CZ 1998-3493	19970410
SK 282837	B6	20021203	SK 1998-1508	19970410
CA 2252898	C	20030408	CA 1997-2252898	19970410
CA 2252898	AA	19971113		
AT 278689	E	20041015	AT 1997-914520	19970410
PT 918772	T	20041231	PT 1997-914520	19970410
PL 188330	B1	20050131	PL 1997-329884	19970410
NZ 332218	A	20050225	NZ 1997-332218	19970410
ES 2229342	T3	20050416	ES 1997-914520	19970410
ZA 9703876	A	19981106	ZA 1997-3876	19970506
HR 970236	B1	20021231	HR 1997-970236	19970507
BG 63544	B1	20020430	BG 1998-102892	19981103
NO 9805194	A	19981106	NO 1998-5194	19981106
NO 312514	B1	20020521		
KR 2000010824	A	20000225	KR 1998-708960	19981106

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

HK 1017892	A1	20030307	HK 1999-102953		19990712
US 6245765	B1	20010612	US 1999-180455		19990830
PRIORITY APPLN. INFO.:			US 1996-16757P	P	19960507
			NZ 1997-332218	A1	19970410
			WO 1997-IB393	W	19970410

IT **146939-27-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)

RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



IT **185021-64-1P 199191-69-0P 199191-70-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)

RN 185021-64-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 199191-70-3 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 199191-69-0 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, trihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 502 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 27 Nov 1997
AB The compds. (I) are prepared by treatment of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one with MeSO3H. I are useful for the treatment of psychotic disorders such as schizophrenia, migraine pain or anxiety (no data). Crystal datas of I are also presented.
ACCESSION NUMBER: 1997:746047 HCAPLUS
DOCUMENT NUMBER: 128:22902
TITLE: Preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders
INVENTOR(S): Busch, Frank R.; Rose, Carol A.
PATENT ASSIGNEE(S): Pfizer Inc., USA; Busch, Frank R.; Rose, Carol A.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742190	A1	19971113	WO 1997-IB306	19970326
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9719368	A1	19971126	AU 1997-19368	19970326
AU 730856	B2	20010315		
EP 904273	A1	19990331	EP 1997-907237	19970326
EP 904273	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CN 1216990	A	19990519	CN 1997-194243	19970326
CN 1092658	B	20021016		
BR 9708932	A	19990803	BR 1997-8932	19970326
JP 11509865	T2	19990831	JP 1997-539668	19970326
JP 3102896	B2	20001023		
NZ 508303	A	20010727	NZ 1997-508303	19970326
IL 126590	A1	20011125	IL 1997-126590	19970326
CZ 289216	B6	20011212	CZ 1998-3494	19970326
CA 2252895	C	20020820	CA 1997-2252895	19970326
CA 2252895	AA	19971113		
SK 282674	B6	20021106	SK 1998-1505	19970326
AT 236902	E	20030415	AT 1997-907237	19970326
PT 904273	T	20030630	PT 1997-907237	19970326
ES 2192264	T3	20031001	ES 1997-907237	19970326
PL 188164	B1	20041231	PL 1997-329880	19970326
NZ 332219	A	20050225	NZ 1997-332219	19970326
TW 427989	B	20010401	TW 1997-86104175	19970401
AP 838	A	20000503	AP 1997-978	19970430
W: BW, GM, KE, MW, UG, ZM, ZW				
ZA 9703875	A	19981106	ZA 1997-3875	19970506

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

HR 970235	B1	20020831	HR 1997-970235	19970507
BG 63601	B1	20020628	BG 1998-102893	19981103
NO 9805193	A	19981106	NO 1998-5193	19981106
NO 312513	B1	20020521		
KR 2000010822	A	20000225	KR 1998-708958	19981106
US 6110918	A	20000829	US 1999-180456	19990302
HK 1017893	A1	20030307	HK 1999-102956	19990712

PRIORITY APPLN. INFO.:

US 1996-16537P	P	19960507
NZ 1997-332219	A1	19970326
WO 1997-IB306	W	19970326

IT **146939-27-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)
RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



IT **185021-64-1P 199191-69-0P 199191-70-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro- 1,3-dihydro-2(1H)-indol-2-one for treatment of psychotic disorders)
RN 185021-64-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 199191-69-0 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, trihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 199191-70-3 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate, dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 503 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 27 Nov 1997
AB Compns. comprise a pharmaceutically acceptable salt of an aryl heterocyclic compound, such as ziprasidone, in a cyclodextrin. Preferred cyclodextrins are β-cyclodextrin sulfbutyl ether (SBECD) and hydroxypropyl β-cyclodextrin (HPBCD). The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution The salt/cyclodextrin inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/mL when the complex is dissolved in water at 40 % weight/volume A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate. A solution was prepared containing SBECD and ziprasidone mesylate.

ACCESSION NUMBER: 1997:745974 HCAPLUS
DOCUMENT NUMBER: 128:39555
TITLE: Inclusion complexes of aryl heterocyclic salts
INVENTOR(S): Johnson, Kevin Charles; Kim, Yesook; Shanker, Ravi Mysore
PATENT ASSIGNEE(S): Pfizer Inc., USA; Johnson, Kevin Charles; Kim, Yesook; Shanker, Ravi Mysore
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9741896	A2	19971113	WO 1997-IB321	19970401
WO 9741896	A3	19980108		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 514529	B	20021221	TW 1997-86103749	19970325
CA 2251912	AA	19971113	CA 1997-2251912	19970401
CA 2251912	C	20030603		
AU 9719372	A1	19971126	AU 1997-19372	19970401
AU 713711	B2	19991209		
EP 900088	A2	19990310	EP 1997-907246	19970401
EP 900088	B1	20040114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CN 1216923	A	19990519	CN 1997-194242	19970401
BR 9709213	A	19990810	BR 1997-9213	19970401
JP 11509866	T2	19990831	JP 1997-539669	19970401
JP 3579060	B2	20041020		
NZ 332220	A	20000327	NZ 1997-332220	19970401
IL 126546	A1	20010128	IL 1997-126546	19970401
SK 282032	B6	20011008	SK 1998-1504	19970401
AT 257714	E	20040115	AT 1997-907246	19970401
PT 900088	T	20040430	PT 1997-907246	19970401
ES 2212809	T3	20040801	ES 1997-907246	19970401
PL 189324	B1	20050729	PL 1997-329928	19970401
ZA 9703874	A	19981106	ZA 1997-3874	19970506
HR 970237	B1	20020430	HR 1997-970237	19970507

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

BG 64474	B1	20050430	BG 1998-102894	19981103
BG 64475	B2	20050430	BG 1998-108606	19981103
US 6232304	B1	20010515	US 1998-147239	19981105
NO 9805192	A	19981106	NO 1998-5192	19981106
KR 2000010823	A	20000225	KR 1998-708959	19981106
US 2001031756	A1	20011018	US 2001-850658	20010507
US 6399777	B2	20020604		

PRIORITY APPLN. INFO.:

US 1996-19204P	P	19960507
WO 1997-IB321	W	19970401
US 1998-147239	A3	19981105

OTHER SOURCE(S): MARPAT 128:39555

IT **122883-93-6D**, Ziprasidone hydrochloride, complexes with cyclodextrin derivs. **146939-27-7D**, Ziprasidone, complexes with cyclodextrin derivs. **185021-64-1D**, complexes with cyclodextrin derivs. **199522-95-7D**, complexes with cyclodextrin derivs. **199522-96-8D**, complexes with cyclodextrin derivs. **199522-97-9D**, complexes with cyclodextrin derivs. **199522-98-0D**, complexes with cyclodextrin derivs. **199522-99-1D**, complexes with cyclodextrin derivs. **199523-00-7D**, complexes with cyclodextrin derivs.
RL: FMU (Formation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(inclusion complexes of aryl heterocyclic salts)

RN 122883-93-6 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 185021-64-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 75-75-2
CMF C H4 O3 S

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 199522-95-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 199522-96-8 HCAPLUS
CN 2-Naphthalenesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 98-11-3
CMF C6 H6 O3 S



RN 199522-98-0 HCAPLUS
CN L-Aspartic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S



CM 2

CRN 120-18-3
CMF C10 H8 O3 S



RN 199522-97-9 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 56-84-8
CMF C4 H7 N O4

Absolute stereochemistry. Rotation (+).



RN 199522-99-1 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 199523-00-7 HCAPLUS
CN Ethanesulfonic acid, compd. with 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 146939-27-7
CMF C21 H21 Cl N4 O S

L6 ANSWER 504 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 594-45-6
CMF C2 H6 O3 S



L6 ANSWER 505 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 12 Nov 1997
AB The authors investigated the spectrum of drug binding of clin. available atypical antipsychotic drugs to multiple dopamine and 5-HT receptors and compared their binding spectrums with typical antipsychotic drugs. It appeared that atypical antipsychotic drugs are, in general, characterized by low D2 dopamine receptor affinity and relatively high affinities for various 5-HT receptors (5HT2A, 5HT2C, 5HT6, 5HT7). The results suggest that since atypical antipsychotic drugs have relatively high affinity for a number of different receptors, ascribing their unique effects to any one receptor is likely to be unproductive.
ACCESSION NUMBER: 1997:712225 HCAPLUS
DOCUMENT NUMBER: 128:18607
TITLE: Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors
AUTHOR(S): Roth, Bryan L.; Meltzer, H. Y.; Khan, Naseem
CORPORATE SOURCE: Deps. Psychiatry, Neuroscis., Biochem. Case Western Res. Univ. Med. Sch., Cleveland, OH, 44106, USA
SOURCE: Advances in Pharmacology (San Diego) (1998), 42(Catecholamines), 482-485
CODEN: ADPHEL; ISSN: 1054-3589
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **146939-27-7**, Ziprasidone
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(binding of typical and atypical antipsychotic drugs to multiple dopamine and 5-HT receptors)
RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 506 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Oct 1997
AB The present invention provides a method for treating pain using an atypical antipsychotic compound Tablet formulations were given for compds. such as risperidone.
ACCESSION NUMBER: 1997:650272 HCAPLUS
DOCUMENT NUMBER: 127:298753
TITLE: Method for treating pain with an atypical antipsychotic compound
INVENTOR(S): Helton, David R.; Shannon, Haarlan E.; Womer, Daniel E.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735584	A1	19971002	WO 1997-US4699	19970324
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2250042	AA	19971002	CA 1997-2250042	19970324
AU 9725872	A1	19971017	AU 1997-25872	19970324
EP 906104	A1	19990407	EP 1997-917594	19970324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
JP 2000507544	T2	20000620	JP 1997-534520	19970324
US 6444665	B1	20020903	US 2000-498047	20000204
US 2003013689	A1	20030116	US 2002-224224	20020815
US 6936601	B2	20050830		
PRIORITY APPLN. INFO.:			US 1996-14152P	P 19960325
			US 1997-823458	B1 19970324
			WO 1997-US4699	W 19970324
			US 2000-498047	A3 20000204

IT **146939-27-7**, Ziprasidone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating pain with atypical antipsychotic compound)
RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 506 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 507 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 17 Sep 1997

AB A method is disclosed for use in assessing, in a subject suffering from a condition which may be treated with a 5-HT2 modulator, the likelihood whether the subject will be responsive or nonresponsive to treatment with a 5-HT2 modulator. The method comprises detecting the presence or absence of DNA encoding the Tyr452 and/or His452 alleles of the 5-HT2A gene in a biol. sample obtained from the subject. Genotyping for His452Tyr polymorphism was carried out using blood samples from individuals diagnosed as suffering from schizophrenia and being treated with clozapine. The individuals were also sep. assessed for responsiveness to clozapine treatment.

ACCESSION NUMBER: 1997:594839 HCAPLUS
DOCUMENT NUMBER: 127:257606
TITLE: Assessment of the responsiveness of individuals to modulators of the 5-HT2 receptors, especially the 5-HT2A receptor, by detection of receptor allele DNA
INVENTOR(S): Kerwin, Robert; Collier, David; Roberts, Gareth Wyn
PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK; Kerwin, Robert; Collier, David; Roberts, Gareth Wyn
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9732037	A1	19970904	WO 1997-EP993	19970226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9718789	A1	19970916	AU 1997-18789	19970226
JP 2000506009	T2	20000523	JP 1997-530621	19970226
ZA 9701775	A	19971128	ZA 1997-1775	19970228
PRIORITY APPLN. INFO.:			GB 1996-4465	A 19960301
			WO 1997-EP993	W 19970226

IT **146939-27-7**, Ziprasidone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(5-HT2 receptor modulator responsiveness assessment by detection of receptor allele DNA)

RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 507 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 508 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 17 Sep 1997

AB A review with 24 refs. Ziprasidone is a novel antipsychotic drug. It has high affinity for serotonin 5-HT2 and dopamine D2 receptors in vitro, with an 11-fold higher affinity for 5-HT2 than for D2 receptors, suggestive of a low potential for inducing motor disturbance [including extrapyramidal symptoms (EPS)]. The effects of ziprasidone in receptor binding studies reflected its in vitro pharmacol., with more potent effects against 5-HT2 receptor-than against D2 receptor-mediated behavior. Because ziprasidone inhibits serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine) reuptake, it may have anxiolytic and antidepressant effects. Data from phase II and III clin. trials have shown ziprasidone to be effective in reducing the pos. and neg. symptoms of, and depression associated with, schizophrenia, and in reducing anxiety in patients about to undergo dental surgery. Ziprasidone was generally well tolerated in phase II and III clin. trials, with somnolence and nausea being the most frequently reported adverse events in placebo-controlled studies. Motor disturbances, including EPS, were infrequently observed

ACCESSION NUMBER: 1997:593623 HCAPLUS
DOCUMENT NUMBER: 127:242699
TITLE: Ziprasidone
AUTHOR(S): Davis, Rick; Markham, Anthony
CORPORATE SOURCE: Adis International Limited, Auckland, N. Z.
SOURCE: CNS Drugs (1997), 8(2), 153-159
CODEN: CNDREF; ISSN: 1172-7047
PUBLISHER: Adis
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

IT **146939-27-7**, Ziprasidone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ziprasidone for psychotic disorders)

RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)



L6 ANSWER 509 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Sep 1997
GI



I

AB Title compound (I) is prepared Thus, ziprasidone was refluxed with PhCH2SH in Me2CHOH to give 90.2% I. In radioligand binding studies for 5HT2 receptors, I showed IC50 = 0.35 nM.

ACCESSION NUMBER: 1997:589196 HCAPLUS
DOCUMENT NUMBER: 127:248126
TITLE: Preparation of prodrugs of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.
INVENTOR(S): Lambert, John Francis; Walinsky, Stanley Walter
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 790236	A1	19970820	EP 1997-200175	19970121
EP 790236	B1	20031119		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 254600	E	20031215	AT 1997-200175	19970121
PT 790236	T	20040430	PT 1997-200175	19970121
ES 2210450	T3	20040701	ES 1997-200175	19970121
CA 2197272	AA	19970814	CA 1997-2197272	19970211
CA 2197272	C	20010123		
JP 09227516	A2	19970902	JP 1997-28993	19970213
JP 2911032	B2	19990623		
PRIORITY APPLN. INFO.:			US 1996-11568P P	19960213

IT **146939-27-7DP**, Ziprasidone, prodrugs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of prodrugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one)
RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 509 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT **195244-33-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of prodrugs of ziprasidone)
RN 195244-33-8 HCAPLUS
CN Piperazine, 1-[2-(6-chloro-2,3-dihydro-2-oxo-1H-indol-5-yl)ethyl]-4-[imino(2-mercaptophenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

IT **195244-32-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prodrug; preparation of prodrugs of ziprasidone)
RN 195244-32-7 HCAPLUS
CN Piperazine, 1-[2-(6-chloro-2,3-dihydro-2-oxo-1H-indol-5-yl)ethyl]-4-[imino(2-mercaptophenyl)methyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 509 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L6 ANSWER 510 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 13 Aug 1997
AB A method of assessing in a subject the likelihood whether said subject will be non-responsive or responsive to treatment with a drug the primary mode of action of which is via a process of altered synaptic activity, the method comprising detecting the presence or absence of DNA comprising the E2 allele of the ApoE gene, or of protein expressed by said DNA, in a biol. sample obtained from said subject. The method is exemplified with an atypical neuroleptic agent, i.e. clozapine.

ACCESSION NUMBER: 1997:511843 HCAPLUS
DOCUMENT NUMBER: 127:117369
TITLE: Method of predicting a subjects response to neuroleptic agents
INVENTOR(S): Royston, Maureen Claire
PATENT ASSIGNEE(S): Smithkline Beecham Plc, UK; Royston, Maureen Claire
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721833	A1	19970619	WO 1996-EP5734	19961211
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9713762	A1	19970703	AU 1997-13762	19961211
ZA 9610458	A	19980612	ZA 1996-10458	19961212
PRIORITY APPLN. INFO.:			GB 1995-25481 A	19951213
			WO 1996-EP5734 W	19961211

IT **146939-27-7**, Ziprasidone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug therapy of schizophrenia and detection of E2 allele of the ApoE gene for prediction of therapeutic outcome)
RN 146939-27-7 HCAPLUS
CN 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- (9CI) (CA INDEX NAME)

L6 ANSWER 510 OF 553 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



10511155amend

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	81.71	250.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.25	-11.25

STN INTERNATIONAL LOGOFF AT 12:07:49 ON 27 APR 2006

10511155amend

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

10511155amend

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:27:10 ON 27 APR 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:27:16 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4
DICTIONARY FILE UPDATES: 26 APR 2006 HIGHEST RN 882003-29-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend8.str



chain nodes :

10511155amend

10 11 12 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
10-11 11-12 12-13
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
2-7 3-9 7-8 8-9 11-12 12-13
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 18:CLASS
Generic attributes :
12:
Saturation : Saturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic
13:
Saturation : Unsaturated

Element Count :
Node 12: Limited
C,C4
N,N2
O,O0
S,S0

Node 13: Limited
C,C4-9

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:27:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 134667 TO ITERATE

10511155amend

1.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 2671670 TO 2715010
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10511155amend9.str



chain nodes :
10 11 21
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
chain bonds :
10-11 11-15 18-21
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20
exact/norm bonds :
2-7 3-9 7-8 8-9 11-15 15-16 15-20 16-17 17-18 18-19 18-21 19-20
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
Generic attributes :
21:
Saturation : Unsaturated

Element Count :
Node 21: Limited
C,C4-9

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l3
SAMPLE SEARCH INITIATED 12:29:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12894 TO ITERATE

15.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 251078 TO 264682
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L3

=> s l3 full
FULL SEARCH INITIATED 12:29:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 257459 TO ITERATE

100.0% PROCESSED 257459 ITERATIONS 21 ANSWERS
SEARCH TIME: 00.00.04

L5 21 SEA SSS FUL L3

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.26	168.47

FILE 'HCAPLUS' ENTERED AT 12:29:45 ON 27 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1907 - 27 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 26 Apr 2006 (20060426/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L6 4 L5

=> d ed abs ibib hitstr 1-4

L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 07 May 2004
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB This invention pertains to a method for producing 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one derivs. with general formula of I [wherein R1 = H or alkyl; n = 1-5] or pharmaceutically acceptable salts thereof. For example, the compound II was prepared in a multi-step synthesis comprising alkylation and hydrolysis starting from ziprasidone. I are useful as antipsychotics (no data).

ACCESSION NUMBER: 2004:370931 HCAPLUS
DOCUMENT NUMBER: 140:375189
TITLE: Process for preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one derivatives
INVENTOR(S): Norris, Timothy; Colon-Cruz, Roberto
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037819	A1	20040506	WO 2003-IB4519	20031013
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2500485	AA	20040506	CA 2003-2500485	20031013
AU 2003269331	A1	20040513	AU 2003-269331	20031013
EP 1556378	A1	20050727	EP 2003-751112	20031013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015516	A	20050823	BR 2003-15516	20031013
JP 2006505578	T2	20060216	JP 2004-546256	20031013
US 2004138232	A1	20040715	US 2003-689773	20031021
US 7019009	B2	20060328		
NO 2005002475	A	20050725	NO 2005-2475	20050523

PRIORITY APPLN. INFO.: US 2002-420843P P 20021024
WO 2003-IB4519 W 20031013

OTHER SOURCE(S): CASREACT 140:375189; MARPAT 140:375189
IT **685567-41-3P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of [(benzisothiazolylpiperazinyl)ethyl]indole

L6 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
derivs.)
RN 685567-41-3 HCAPLUS
CN Butanedioic acid, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1-(4-ethoxy-1,4-dioxobutyl)-1H-indol-2-yl ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OEt

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 Oct 2003
GI



I

II



III

Appl.

AB Title compds. I [R1 = H, A, SO2A; A = alkyl, alkoxyalkyl; D-E = R2C=CR4, R2R3C-CR4R5; R2, R3, R4, R5 = H, A, cycloalkyl, etc.; X1 = (CHR7)g, (CHR7)h-Q-(CHR8)k; Q = O, S, NR6, etc.; R6 = H, A, cycloalkyl; R7, R8, R12 = definition as given for R2-R5; g = 1-6; h, k = 0-6; p = 0-3; E = H, A, cycloalkyl, etc.; G = (un)substituted alkylene; E and G together form (un)substituted mono or bicyclic heterocycle; X2 = definition as given for X1; Z = H, (un)substituted aromatic carbocyle] and their pharmaceutically acceptable salts and formulations were prepared For example, N-alkylation of 4-(4-fluorobenzyl)piperideine with methanesulfonic ester II, e.g., prepared from indole-4-carboxylic acid Me ester in 7-steps, afforded the hydrochloride salt of indole-3-carbonitrile III after work-up. Compds. I are claimed useful as excitatory amino acid antagonists (no data provided) and as 5-HT reuptake inhibitors.

ACCESSION NUMBER: 2003:837073 HCAPLUS
DOCUMENT NUMBER: 139:337888
TITLE: Preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases
INVENTOR(S): Schadt, Oliver; Boettcher, Henning; Leibrock, Joachim; Schiemann, Kai; Heinrich, Timo; Hoelzemann, Guenter; Van Amsterdam, Christoph; Bartoszyk, Gerd; Seyfried, Christoph
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087086	A2	20031023	WO 2003-EP3806	20030411
WO 2003087086	A3	20040722		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10217006	A1	20031106	DE 2002-10217006	20020416
CA 2482655	AA	20031023	CA 2003-2482655	20030411
AU 2003224064	A1	20031027	AU 2003-224064	20030411
EP 1497279	A2	20050119	EP 2003-720455	20030411
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005153980	A1	20050714	US 2003-511155	20030411
JP 2005523310	T2	20050804	JP 2003-584042	20030411

PRIORITY APPLN. INFO.: DE 2002-10217006 A 20020416
WO 2003-EP3806 W 20030411

OTHER SOURCE(S): MARPAT 139:337888
IT **615569-38-5P 615569-39-6P 615569-40-9P 615569-41-0P 615569-42-1P 615569-44-3P 615569-46-5P 615569-47-6P 615569-54-5P 615569-60-3P 615569-62-5P 615569-63-6P 615569-66-9P 615569-71-6P 615569-72-7P 615569-73-8P 615569-77-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of indole-3-carbonitriles as excitatory amino acid antagonists for the treatment of neurodegenerative diseases)
RN 615569-38-5 HCAPLUS
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-6-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-39-6 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2-oxo-2H-1-benzopyran-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 615569-40-9 HCAPLUS
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-4-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-41-0 HCAPLUS
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 615569-42-1 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1H-indol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 615569-44-3 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,1,3-benzothiadiazol-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 615569-46-5 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(8-quinolinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 615569-47-6 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)





L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 615569-54-5 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 615569-60-3 HCAPLUS
CN Acetamide, N-[6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]- (9CI) (CA INDEX NAME)



RN 615569-62-5 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 615569-63-6 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(2-pyrimidinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 615569-66-9 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-4-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 615569-71-6 HCAPLUS
CN Carbamic acid, [6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 615569-72-7 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[3-[4-(3-amino-2-oxo-2H-1-benzopyran-6-yl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)



RN 615569-73-8 HCAPLUS
CN Carbamic acid, [6-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-2-oxo-2H-1-benzopyran-3-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 615569-77-2 HCAPLUS

L6 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Benzofurancarboxamide, 5-[4-[3-(3-cyano-1H-indol-5-yl)propyl]-1-piperazinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L6 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 06 Aug 2002
AB Bifunctional mol., which possesses photoconductive and electrooptic properties in one mol., was synthesized as a new photorefractive material. Carbazole as a photoconductive moiety was covalently bound to thiophene derivative as an electrooptic chromophore via a flexible alkyl chain. The sample prepared from the mixture of bifunctional mol. (89 weight%), 2,4,7-trinitro-9-fluorenone (1 weight%) and ethylcarbazole (10 weight%) showed good photorefractive property. The 50 μm thick film showed the maximum diffraction efficiency of 65% at 70 V/μm, corresponding to a refractive index modulation (Δn) of ca. 4.5+10-3.
ACCESSION NUMBER: 2002:585265 HCAPLUS
DOCUMENT NUMBER: 138:80573
TITLE: Synthesis and characterization of organic photorefractive glass
AUTHOR(S): Chun, Hyunsee; Kim, Nam-Jun; Joo, Won-Jae; Han, Jae Wook; Oh, Chang Ho; Kim, Nakjoong
CORPORATE SOURCE: Center for Organic Photorefractive Materials, Department of Chemistry, Hanyang University, Seoul, 133-791, S. Korea
SOURCE: Synthetic Metals (2002), 129(3), 281-283
CODEN: SYMEDZ; ISSN: 0379-6779
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **481025-54-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in preparation of photorefractive glass material)
RN 481025-54-1 HCAPLUS
CN 2-Thiophenecarboxaldehyde, 5-[4-[6-(9-ethyl-9H-carbazol-3-yl)-6-methoxyhexyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



IT **481025-59-6P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and characterization of organic photorefractive glass)
RN 481025-59-6 HCAPLUS
CN Propanedinitrile, [[5-[4-[6-(9-ethyl-9H-carbazol-3-yl)-6-methoxyhexyl]-1-piperazinyl]-2-thienyl]methylene]- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 02 Mar 2001
GI



I

AB Title compds. [I; R1 = R(CH2)nZZ1; R = (un)substituted naphthyl or heteroannelated Ph; R2R3 = atoms to complete a thiophene, furan, or (oxo)pyrrole ring; Z = bons, O, [(ar)alkyl]imino; Z1 = 1,4-cyclohexylene, piperidine-1,4- or -4,1-diyl, piperazine-1,4-diyl; n = 1-6] were prepared Thus, 7-chlorofuro[2,3-c]pyridine was aminated by N-(2-naphthylmethyl)-4-piperidineamine to give I (R1 = RCH2NHZ1, R = 2-naphthyl, R2R3 = OCH:CH, Z1 = piperidine-4,1-diyl). Data for biol. activity of I were given.
ACCESSION NUMBER: 2001:152309 HCAPLUS
DOCUMENT NUMBER: 134:193415
TITLE: Preparation of heteroannelated pyridines as 5-HT1A receptor ligands
INVENTOR(S): Peglion, Jean-louis; Dessinges, Aimee; Poitevin, Christophe; Millan, Mark; Dekeyne, Anne
PATENT ASSIGNEE(S): Adir Et Compagnie, Fr.; Les Laboratoires Servier
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1078928	A1	20010228	EP 2000-402359	20000825
EP 1078928	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2797874	A1	20010302	FR 1999-10834	19990827
FR 2797874	B1	20020329		
US 6399616	B1	20020604	US 2000-641777	20000818
JP 2001097978	A2	20010410	JP 2000-252191	20000823
JP 3602780	B2	20041215		
CA 2317053	AA	20010227	CA 2000-2317053	20000825
ZA 2000004411	A	20010228	ZA 2000-4411	20000825
CN 1286255	A	20010307	CN 2000-124065	20000825
AT 266664	E	20040515	AT 2000-402359	20000825
PT 1078928	T	20040930	PT 2000-402359	20000825
ES 2220359	T3	20041216	ES 2000-402359	20000825
NO 2000004295	A	20010228	NO 2000-4295	20000828
NO 316651	B1	20040322		
BR 2000003848	A	20010403	BR 2000-3848	20000828
AU 765661	B2	20030925	AU 2000-53642	20000828
HK 1034250	A1	20050429	HK 2001-104815	20010711
US 2002161228	A1	20021031	US 2002-105171	20020325
US 6486171	B2	20021126		

PRIORITY APPLN. INFO.: FR 1999-10834 A 19990827
US 2000-641777 A3 20000818
OTHER SOURCE(S): MARPAT 134:193415
IT **327173-35-3P**

L6 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroannelated pyridines as 5-HT1A receptor ligands)
RN 327173-35-3 HCAPLUS
CN Furo[3,2-c]pyridine, 4-[4-[2-(1H-indol-5-yl)ethyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10511155amend

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.97	191.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

STN INTERNATIONAL LOGOFF AT 12:30:26 ON 27 APR 2006